Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes

European Journal of Heart Failure

Volumn 19, Issue 3, 2017, Pages 326-336

  Mátyás, Csaba ^a   Németh, Balázs T ^a   Oláh, Attila ^a   Török, Marianna ^a   Ruppert, Mihály ^a   Kellermayer, Dalma ^a   Barta, Bálint A ^a   Szabó, Gábor ^b   Kökény, Gábor ^a   Horváth, Eszter M ^a   Bódi, Beáta ^c   Papp, Zoltán ^c   Merkely, Béla ^a   Radovits, Tamás ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Cardiomyocyte stiffness; cGMP; Diabetic cardiomyopathy; Diastolic dysfunction; Vardenafil

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; VARDENAFIL; PHOSPHODIESTERASE V INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDIAC MUSCLE CELL; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; IN VIVO STUDY; LIMIT OF QUANTITATION; NITRO OXIDATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RAT; SIGNAL TRANSDUCTION; ANIMAL; CARDIAC MUSCLE; CARDIOMEGALY; DIAGNOSTIC IMAGING; DRUG EFFECTS; FIBROSIS; HEART; HEART FAILURE; HEART STROKE VOLUME; METABOLISM; PATHOLOGY; ZUCKER RAT;

ANIMALS; APOPTOSIS; CARDIOMEGALY; CYCLIC GMP; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; FIBROSIS; HEART; HEART FAILURE; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PHOSPHODIESTERASE 5 INHIBITORS; RATS; RATS, ZUCKER; STROKE VOLUME; VARDENAFIL DIHYDROCHLORIDE;

EID: 85007236091     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.711     Document Type: Article

References (30)

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
2. Zouein FA, de Castro Bras LE, da Costa DV, Lindsey ML, Kurdi M, Booz GW. Heart failure with preserved ejection fraction: emerging drug strategies. J Cardiovasc Pharmacol 2013;62:13–21.
3. Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 2014;142:375–415.
4. Zhao CY, Greenstein JL, Winslow RL. Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network. J Mol Cell Cardiol 2016;91:215–227.
5. Matyas C, Nemeth BT, Olah A, Hidi L, Birtalan E, Kellermayer D, Ruppert M, Korkmaz-Icoz S, Kokeny G, Horvath EM, Szabo G, Merkely B, Radovits T. The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus. Cardiovasc Diabetol 2015;14:145.
6. Das A, Durrant D, Salloum FN, Xi L, Kukreja RC. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther 2015;147:12–21.
7. van Heerebeek L, Hamdani N, Falcao-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, van der Velden J, Stienen GJ, Laarman GJ, Somsen A, Verheugt FW, Niessen HW, Paulus WJ. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 2012;126:830–839.
8. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263–271.
9. Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res. 2004;16(Suppl 1):S11–S14.
10. Szabo G, Radovits T, Veres G, Krieger N, Loganathan S, Sandner P, Karck M. Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass. Eur J Cardiothorac Surg 2009;36:657–664.
11. Loganathan S, Radovits T, Hirschberg K, Korkmaz S, Barnucz E, Karck M, Szabo G. Effects of selective phosphodiesterase-5-inhibition on myocardial contractility and reperfusion injury after heart transplantation. Transplantation 2008;86:1414–1418.
12. Radovits T, Bomicke T, Kokeny G, Arif R, Loganathan S, Kecsan K, Korkmaz S, Barnucz E, Sandner P, Karck M, Szabo G. The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. Br J Pharmacol 2009;156:909–919.
13. Ellis CG, Goldman D, Hanson M, Stephenson AH, Milkovich S, Benlamri A, Ellsworth ML, Sprague RS. Defects in oxygen supply to skeletal muscle of prediabetic ZDF rats. Am J Physiol Heart Circ Physiol 2010;298:H1661–H1670.
14. Conceicao G, Heinonen I, Lourenco AP, Duncker DJ, Falcao-Pires I. Animal models of heart failure with preserved ejection fraction. Neth Heart J 2016;24:275–286.
15. Radovits T, Olah A, Lux A, Nemeth BT, Hidi L, Birtalan E, Kellermayer D, Matyas C, Szabo G, Merkely B. Rat model of exercise-induced cardiac hypertrophy: hemodynamic characterization using left ventricular pressure–volume analysis. Am J Physiol Heart Circ Physiol 2013;305:H124–H134.
16. Varga ZV, Giricz Z, Liaudet L, Hasko G, Ferdinandy P, Pacher P. Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. Biochim Biophys Acta 2015; 1852:232–242.
17. Radovits T, Arif R, Bomicke T, Korkmaz S, Barnucz E, Karck M, Merkely B, Szabo G. Vascular dysfunction induced by hypochlorite is improved by the selective phosphodiesterase-5-inhibitor vardenafil. Eur J Pharmacol 2013;710:110–119.
18. Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, Xi L. Cardioprotection with phosphodiesterase-5 inhibition – a novel preconditioning strategy. J Mol Cell Cardiol 2004;36:165–173.
19. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E. RELAX Trial Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013;309:1268–1277.
20. Franssen C, Gonzalez Miqueo A. The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. Neth Heart J 2016;24:259–267.
21. Giannetta E, Isidori AM, Galea N, Carbone I, Mandosi E, Vizza CD, Naro F, Morano S, Fedele F, Lenzi A. Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 2012;125:2323–2333.
22. Koka S, Aluri HS, Xi L, Lesnefsky EJ, Kukreja RC. Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1alpha signaling. Am J Physiol Heart Circ Physiol 2014;306:H1558–H1568.
23. Radovits T, Korkmaz S, Matyas C, Olah A, Nemeth BT, Pali S, Hirschberg K, Zubarevich A, Gwanmesia PN, Li S, Loganathan S, Barnucz E, Merkely B, Szabo G. An altered pattern of myocardial histopathological and molecular changes underlies the different characteristics of type-1 and type-2 diabetic cardiac dysfunction. J Diabetes Res 2015;2015:728741.
24. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschope C, Leite-Moreira AF, Musters R, Niessen HW, Linke WA, Paulus WJ, Hamdani N. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail 2016;4:312–324.
25. Hamdani N, Franssen C, Lourenco A, Falcao-Pires I, Fontoura D, Leite S, Plettig L, Lopez B, Ottenheijm CA, Becher PM, Gonzalez A, Tschope C, Diez J, Linke WA, Leite-Moreira AF, Paulus WJ. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail 2013;6:1239–1249.
26. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87:315–424.
27. Zarain-Herzberg A, Garcia-Rivas G, Estrada-Aviles R. Regulation of SERCA pumps expression in diabetes. Cell Calcium 2014;56:302–310.
28. Dias-Junior CA, Neto-Neves EM, Montenegro MF, Tanus-Santos JE. Hemodynamic effects of inducible nitric oxide synthase inhibition combined with sildenafil during acute pulmonary embolism. Nitric Oxide 2010;23:284–288.
29. Van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N, Richter U, Fischer JW, Bohm M, Pauschinger M, Schultheiss HP, Tschope C. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 2008;103:319–327.
30. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214–222.